FDA approves Lannett’s generic Urecholine

PHILADELPHIA Philadelphia-based Lannett Co. has announced that it received approval from the Food and Drug Administration of its application for bethanechol chloride tablets, the generic equivalent of Urecholine, marketed by Odyssey Pharmaceuticals.

The medication, designed, Lannett stated, to speed the passage of foods through the digestive tract, will be available in 5 mg, 10 mg, 25 mg, and 50 mg tablets.

“This approval represents an important new addition to our product portfolio and is the result of the hard work and dedication of our employees,” Arthur Bedrosian, Lannett’s president and chief executive officer, said in a company release.

Total sales of generic bethanechol chloride tablets were $60 million in 2007, according to data from Wolters Kluwer.